Keryx Biopharmaceuticals (NASDAQ:KERX) has been assigned a consensus rating of “Hold” from the eleven research firms that are covering the stock. Six research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $8.42.

Separately, Maxim Group restated a “buy” rating and set a $7.00 price objective on shares of Keryx Biopharmaceuticals in a research note on Monday, May 1st.

Keryx Biopharmaceuticals (NASDAQ:KERX) traded up 0.64% during midday trading on Monday, reaching $6.32. The company’s stock had a trading volume of 910,001 shares. The firm’s market capitalization is $685.51 million. The firm has a 50 day moving average price of $6.04 and a 200 day moving average price of $5.69. Keryx Biopharmaceuticals has a 1-year low of $4.03 and a 1-year high of $7.80.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by $0.03. Keryx Biopharmaceuticals had a negative return on equity of 270.26% and a negative net margin of 584.76%. The company had revenue of $11.82 million for the quarter, compared to the consensus estimate of $10.19 million. During the same quarter last year, the business earned ($0.39) EPS. Keryx Biopharmaceuticals’s revenue was up 73.2% on a year-over-year basis. On average, analysts predict that Keryx Biopharmaceuticals will post ($0.69) EPS for the current year.

Several institutional investors have recently modified their holdings of KERX. OZ Management LP acquired a new position in shares of Keryx Biopharmaceuticals during the first quarter valued at about $109,000. Usca Ria LLC acquired a new position in shares of Keryx Biopharmaceuticals during the first quarter valued at about $128,000. Green Square Capital LLC acquired a new position in shares of Keryx Biopharmaceuticals during the third quarter valued at about $135,000. Jane Street Group LLC acquired a new position in shares of Keryx Biopharmaceuticals during the first quarter valued at about $141,000. Finally, Lincoln Capital Corp acquired a new position in shares of Keryx Biopharmaceuticals during the fourth quarter valued at about $158,000. Institutional investors own 61.74% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Keryx Biopharmaceuticals (KERX) Receives Average Rating of “Hold” from Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/05/22/keryx-biopharmaceuticals-kerx-receives-average-rating-of-hold-from-analysts.html.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

12 Month Chart for NASDAQ:KERX

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.